GLP-1 medications are not FDA-approved to treat type 1 diabetes, but adults with type 1 diabetes who also carry insulin resistance or obesity are increasingly prescribed them off-label, under close endocrine supervision, to lower insulin requirements and support weight loss.

TL;DR

  • No GLP-1 is FDA-approved for type 1 diabetes in 2026, so every use is off-label and requires physician oversight.
  • Ozempic and Mounjaro are the most common off-label picks for adults with type 1 diabetes and insulin resistance: Consider.
  • Compounded semaglutide or tirzepatide is never appropriate here given the added hypoglycemia and DKA monitoring burden: Skip.
  • Continuous glucose monitoring and a formal insulin retitration plan are non-negotiable before the first dose.
Key Takeaways
  • Every GLP-1 use in type 1 diabetes is off-label in 2026 and needs a physician actively reading labs, not an auto-refill app.
  • Ozempic and Mounjaro are the most-considered options; compounded semaglutide or tirzepatide should be skipped entirely.
  • Continuous glucose monitoring and a written insulin retitration schedule must be in place before the first dose.
  • Small studies report insulin dose reductions of 10-20% as appetite and gastric emptying change on a GLP-1.
  • GoodLife Health's flat $299 monthly membership doesn't increase as your dose escalates, removing the incentive to titrate faster than your glucose control can handle.
  • This approach is for people with an existing insulin regimen and "double diabetes," not for anyone newly diagnosed, recently hospitalized for DKA, or underweight.

Why This Matters

Type 1 diabetes is an insulin-deficiency disease. GLP-1 medications were built and tested for type 2 diabetes and obesity, where the pancreas still makes some insulin. That distinction matters because a GLP-1 slows gastric emptying and blunts appetite, both of which change how much insulin a person actually needs and when.

Clinical note

Get that timing wrong in someone dependent on injected insulin and you get two opposite failure modes: dangerous hypoglycemia if the insulin dose isn't cut back, or diabetic ketoacidosis if illness or reduced intake isn't managed carefully. Neither is a reason to avoid GLP-1 therapy outright. It is the reason it needs a physician who reads labs, not an app that just refills a script.

Who This Is For

This guide is for an adult with established type 1 diabetes who is also carrying excess weight, showing signs of insulin resistance (rising total daily insulin dose without matching carbohydrate intake), or managing what some clinicians call "double diabetes": type 1 diabetes layered on top of metabolic syndrome. It assumes you already have a working basal-bolal insulin regimen and an endocrinologist or primary care clinician actively managing your glucose control, and you're exploring whether a GLP-1 belongs in that regimen as an adjunct, not a replacement. GoodLife Health's clinicians evaluate GLP-1 candidacy inside the Cardiometabolic Optimization Membership by reading the full biomarker picture, not a weight-loss request alone, before any prescription is written.

This is not for someone newly diagnosed, someone with a recent DKA hospitalization, or someone underweight relative to their frame. Those situations call for stabilization first.

What to Look For in a GLP-1 Plan for Type 1 Diabetes

FDA approval status, stated plainly

Ask any provider point blank whether the drug they're prescribing is FDA-approved for your diagnosis. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy, Zepbound, Wegovy Tablets, and Foundayo are approved for chronic weight management. None carry a type 1 diabetes indication in 2026, and a provider who tells you otherwise is misrepresenting the label.

A hypoglycemia and CGM requirement, not a suggestion

GLP-1s don't cause hypoglycemia on their own, but they change how fast carbohydrates hit your bloodstream relative to your insulin dose. A plan without continuous glucose monitoring data feeding the insulin adjustment decisions is a plan flying blind. This should be built into the protocol from week one, not added after a low blood sugar event.

A defined insulin retitration schedule

Small clinical studies of adjunct GLP-1 therapy in type 1 diabetes have reported insulin dose reductions in the range of 10-20% as appetite and gastric emptying change. That range is not a promise for any individual, but it tells you retitration is expected, not exceptional. Your clinician should have a written plan for when and how much to cut basal and bolus doses, not a wait-and-see approach.

What the numbers show
10-20%
Reported insulin dose reduction with adjunct GLP-1 therapy in type 1 diabetes
$299
Monthly Cardiometabolic Optimization Membership, flat fee regardless of dose
90 days
Biomarker Audit cadence (HbA1c, lipids, inflammation markers)
15%
Average weight loss on semaglutide (STEP-1, non-type 1 population)
22.5%
Average weight loss on tirzepatide (SURMOUNT-1, non-type 1 population)

GI tolerability planned around insulin timing

Nausea and slowed digestion change how carbohydrates absorb, which changes how your bolus insulin should be timed. The GLP-1 titration schedule matters more in type 1 diabetes than in any other population, because a skipped meal from nausea combined with an unadjusted insulin dose is how hypoglycemia happens.

Physician oversight cadence, not a one-time consult

A single telehealth visit and an auto-refill is not oversight for someone insulin-dependent. Look for a model built on recurring lab review. GoodLife Health's Biomarker Audit runs every 90 days and includes HbA1c, lipids, and inflammation markers alongside the weight-loss and hormone panels, so dose decisions are made against current data, not a memory of last year's labs.

Cost structure that doesn't reward dose escalation

Some telehealth weight-loss platforms increase what they charge as your dose goes up. That creates a financial incentive to escalate faster than your body, and your glucose control, can tolerate. GoodLife Health's membership is one flat fee for the doctor. Zero markup on the medicine: the $299 monthly membership doesn't change because your dose changes, and the medication itself bills at pharmacy cost.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

Top Options Clinicians Consider

Ozempic (semaglutide): the familiar pick. FDA-approved for type 2 diabetes, it's the drug most endocrinologists have the most off-label experience prescribing alongside insulin. Weekly injection, gradual titration schedule, and a track record stretching back to 2017 for the molecule. Consider for adults with type 1 diabetes and clear insulin resistance, under active glucose monitoring.

Mounjaro (tirzepatide): the stronger appetite effect. Same molecule as Zepbound, dual GIP/GLP-1 action, and FDA-approved for type 2 diabetes specifically. Read the tirzepatide for adults with type 2 diabetes breakdown for how the dosing schedule works before assuming it transfers cleanly to type 1 diabetes management, because the appetite suppression is pronounced enough that insulin retitration needs to happen faster. Consider, with a tighter CGM check-in cadence than semaglutide typically requires.

Wegovy: approved for chronic weight management, not diabetes, but frequently the label a clinician reaches for when the primary goal is weight loss rather than glycemic control. Same active ingredient as Ozempic at a different dose ceiling. Consider if weight loss, not insulin sensitivity, is the stated priority.

Zepbound: the cash-pay counterpart to Mounjaro, approved for weight management. If you're paying out of pocket rather than routing through insurance for a type 2 diagnosis you don't have, this is the FDA-approved lane rather than an off-label prescription of Mounjaro. Consider.

Foundayo (oral orforglipron): the newest branded oral GLP-1 option, no injection required. Less real-world data exists on oral GLP-1s in insulin-dependent patients specifically as of 2026. Consider cautiously, and only with a clinician comfortable adjusting insulin against a less established side-effect timeline.

What to Avoid

  • Compounded semaglutide or tirzepatide. These are not FDA-approved formulations, dosing consistency isn't guaranteed, and adding that uncertainty on top of insulin dependence is not a reasonable trade. Read why compounded semaglutide carries real safety and legal questions in 2026 before considering it.
  • Any provider that doesn't ask for your current insulin regimen before prescribing. If a telehealth intake form doesn't ask your total daily dose, your basal insulin, and your CGM data, that provider isn't equipped to manage the interaction.
  • Aggressive dose escalation on someone else's timeline. Type 1 diabetes management should slow the titration schedule down, not speed it up. A plan that pushes to the maximum dose in 8-12 weeks regardless of your glucose trends is optimizing for the wrong outcome.

A GLP-1 does not replace insulin; it changes how much insulin you need.

Verdict at a Glance

Verdict at a Glance

MedicationFDA StatusType 1 Diabetes FitVerdict
Ozempic (semaglutide)Approved for type 2 diabetesOff-label, most clinical experienceConsider
Mounjaro (tirzepatide)Approved for type 2 diabetesOff-label, faster insulin retitration neededConsider
Wegovy (semaglutide)Approved for weight managementOff-label for glycemic goalsConsider
Zepbound (tirzepatide)Approved for weight managementOff-label for glycemic goalsConsider
Foundayo (orforglipron)Approved for weight managementLimited insulin-dependent dataConsider cautiously
Compounded semaglutide/tirzepatideNot FDA-approvedNot appropriateSkip

Care in every case is delivered by board-certified physicians working under GoodLife Health's clinical protocols, licensed in all 50 states. A compounding pharmacy never substitutes for physician judgment.

FAQ

Is Ozempic approved for type 1 diabetes?

No. Ozempic is FDA-approved for type 2 diabetes, not type 1. Any use in a person with type 1 diabetes is off-label and requires physician supervision of insulin dosing.

Can someone with type 1 diabetes take Wegovy or Zepbound?

Yes, off-label, if a clinician determines the weight-loss benefit outweighs the added monitoring burden. Both are FDA-approved for weight management, not for type 1 diabetes specifically, so insulin adjustments still need active oversight.

Does a GLP-1 lower insulin needs in type 1 diabetes?

Often, yes. Small studies of adjunct GLP-1 therapy in type 1 diabetes report insulin dose reductions in the 10-20% range as appetite and gastric emptying change, though individual results vary and retitration must be planned, not improvised.

What is double diabetes?

Double diabetes describes type 1 diabetes combined with insulin resistance or obesity typically associated with type 2 diabetes. It's the primary group of type 1 diabetes patients for whom GLP-1 therapy is being considered off-label in 2026.

Is compounded semaglutide safe for type 1 diabetes patients?

No. Compounded semaglutide and tirzepatide are not FDA-approved formulations, and the dosing inconsistency they carry is a bad match for someone whose insulin dose must track drug effect precisely. Branded GLP-1s only.

How much weight loss can someone with type 1 diabetes expect on a GLP-1?

Trial data in non-type 1 populations shows roughly 15% average weight loss on semaglutide (STEP-1) and up to roughly 22.5% on tirzepatide (SURMOUNT-1). Type 1 diabetes-specific outcomes vary by individual and aren't the same population studied in those trials.

Does GLP-1 use increase DKA risk in type 1 diabetes?

The medication itself doesn't directly cause DKA, but reduced food intake from nausea combined with an unadjusted insulin dose can trigger it. Continuous glucose monitoring and a clear sick-day insulin plan reduce that risk substantially.

Who prescribes GLP-1 medications for adults with type 1 diabetes?

Board-certified physicians experienced in insulin management, typically an endocrinologist or a primary care clinician working from current lab data. GoodLife Health's clinicians make this decision using quarterly Biomarker Audit results rather than a single intake form.

One Last Thing

Most of the caution around GLP-1 therapy in type 1 diabetes is about timing rather than the drug itself. The insulin dose that worked on Monday can be too high by Thursday once appetite drops, and the adjustment window is measured in days, not the standard 90-day follow-up cadence most weight-loss programs run on. Anyone starting a GLP-1 with type 1 diabetes should have a way to reach their clinician inside that window, not just at the next scheduled visit.

Related Guides

References

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/